Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales
Publishing timestamp: 2024-02-01 11:07:40
Summary
Merck reported fourth-quarter revenue and adjusted earnings that exceeded expectations, driven by strong demand for its cancer drug Keytruda and HPV vaccine Gardasil. However, the company also posted a net loss due to charges related to a collaboration deal. Merck's CEO expressed optimism about the company's progress and its plans for future growth. The article also mentions the performance of other drugs in Merck's portfolio and provides information on the company's full-year guidance and restructuring plans.
Sentiment: MIXED
Tickers: MRK, 4568.T-JP, HARP,
Keywords: business, biotech and pharmaceuticals, merck & co inc, earnings, harpoon therapeutics inc, health care industry, breaking news, business news, pharmaceuticals, biotechnology, daiichi sankyo co ltd,
Source: https://www.cnbc.com/2024/02/01/merck-mrk-q4-earnings-report-2023.html